Preface

This summary addresses “deregulated nutrient sensing” as a hallmark of ageing and the interventions used in longevity practice to modulate it. Note at the outset that no intervention in this domain is licensed by the MHRA, EMA or FDA for slowing ageing or extending lifespan; every therapeutic use described below is off-label, experimental, or supported only by surrogate/biomarker data, and human hard-outcome evidence (mortality, morbidity, function) remains limited.[1][2][3] This document is intended as adjunctive to, never a replacement for, conventional primary and secondary care.

1. Scope

– Covered: The biology of the four canonical nutrient-sensing axes (insulin/IGF-1 signalling [IIS], mTOR/mTORC1, AMPK, sirtuins/NAD⁺) and their deregulation with ageing; and the interventions most commonly used to modulate them in longevity clinics — dietary restriction and time-restricted eating, metformin, low-dose intermittent rapamycin (sirolimus), NAD⁺ precursors (nicotinamide riboside [NR], nicotinamide mononucleotide [NMN]), spermidine, and (contextually) SGLT2 inhibitors as calorie-restriction mimetics.[4][5][6][3][7][8]

– Target population: Community-dwelling adults attending a private longevity/preventive clinic, typically mid-life onwards, alongside conventional care.

– Not covered: Management of overt type 2 diabetes, licensed oncological/transplant use of mTOR inhibitors, paediatric use, senolytics/senomorphics as a distinct class, and detailed dietary-pattern prescription (Mediterranean/Okinawan). Animal and in-vitro data are quarantined to a clearly marked preclinical subsection.

2. Background and pathophysiology

Nutrient-sensing pathways detect fluctuations in nutrient/energy supply and switch cells between anabolic growth and catabolic maintenance/repair.[9][10] The core logic:

– Nutrient-abundance sensors — insulin/IGF-1 and mTORC1 — are activated by glucose, amino acids and growth factors, driving protein/lipid synthesis and suppressing autophagy.[9][11]

– Nutrient-scarcity sensors — AMPK (high AMP:ATP) and sirtuins (high NAD⁺:NADH) — are activated by fasting, caloric restriction and exercise, promoting mitochondrial biogenesis, mitophagy and autophagy.[9][4]

“Deregulated nutrient sensing” refers to the age-related shift toward persistent mTOR/IIS activation with blunted AMPK/sirtuin signalling and declining NAD⁺, contributing to loss of proteostasis, mitochondrial dysfunction, cellular senescence and stem-cell exhaustion.[10][11][9] It is explicitly implicated in the biology of frailty: in rhesus monkeys long-term caloric restriction prevented the Fried frailty phenotype.[12]

The following schematic from Nature Reviews Endocrinology integrates how caloric state modulates SIRT/AMPK/TOR/IIS and downstream FOXO and PGC-1α to control mitochondrial health:

Figure 1 Longevity signalling pathways control mitochondrial health. Caloric restriction reduces the concentrations of glucose, amino acids and lipids, while raising the concentrations of key metabolites, such as NAD + and AMP. These metabolites modulate the activity of metabolic sensors, such as the sirtuins (SIRTs), AMP kinase (AMPK), the target of rapamycin (TOR) and insulin–IGF1 signalling (IIS). Downstream to metabolic sensors, transcription factors, such as forkhead box O (FOXO) and the peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α), orchestrate mitochondrial physiology and homeostasis. Dysregulation of this multilevel regulatory system reduces mitochondrial homeostasis, resulting in frailty and disease. Ac, acetyl group; ACC, acetyl-CoA carboxylase; LKB1, liver kinase B1; ULK1, UNC51-like kinase 1.

The single most robust human observation underpinning this hallmark is genetic: loss-of-function variation in the GH/IGF-1 somatotropic axis is associated with exceptional human longevity, and the pathways are highly interconnected.[10][14] Beyond genetics and the consistent physiology of dietary restriction, direct human evidence that pharmacologically manipulating these pathways changes ageing outcomes is preliminary.

Preclinical only (mechanistic plausibility — do not extrapolate to hard clinical benefit): rapamycin, metformin (synergistic with rapamycin in the NIA Interventions Testing Program), resveratrol/SRT1720, spermidine and NAD⁺ repletion each extend lifespan or healthspan in yeast, worms, flies and/or mice.[15][16][17] Metformin alone did not significantly extend lifespan in the NIA ITP.[16]

3. Evidence base and grading

Available human evidence is dominated by small, short RCTs with surrogate/biomarker endpoints, mechanistic physiology studies, and observational cohorts (mostly in diabetes). No completed RCT has tested slowing of human ageing as a primary hard outcome; TAME (metformin) and VA-IMPACT are designed to address this but are pending/ongoing.[5] GRADE-style certainty per major outcome:

Intervention / outcome	Evidence statement	Certainty (GRADE)	Recommendation
Dietary/caloric restriction & TRE → metabolic/ageing biomarkers	Consistent human physiology plus primate frailty data; hard longevity outcomes in humans lacking	Low–Moderate (indirectness, adherence)	Conditional recommendation (offer as lifestyle) [4], [12], [18]
Metformin → all-cause mortality/CV outcomes (in diabetes)	Large observational data suggest reduced mortality; not generalisable to non-diabetic ageing	Moderate (in diabetes); Very low (for healthy ageing — indirectness)	Recommend against routine use solely for longevity in non-diabetics outside trials [5], [16]
Metformin → exercise adaptation (older adults)	2 RCTs (MASTERS n=94; AET n=53): metformin blunts resistance hypertrophy and aerobic mitochondrial/VO₂max gains	Moderate	Recommend against combining with structured exercise-for-longevity programmes [19], [20], [21]
Low-dose intermittent rapamycin → safety	PEARL RCT (n≈100, 48 wk, 5–10 mg/wk): AEs similar to placebo; no change in visceral fat	Low–Moderate (surrogate endpoints, self-selected cohort)	Only in research / conditional with informed consent [2], [6]
Rapamycin → muscle/functional gains with exercise	RAPA-EX-01 RCT: weekly 6 mg attenuated chair-stand gains vs placebo	Low–Moderate	Recommend against pairing with exercise training [22], [23]
NAD⁺ precursors (NR/NMN) → healthspan outcomes	~28 RCTs: reliable NAD⁺ target engagement, good tolerability, but functional/metabolic effects null or endpoint-specific	Low (inconsistency, imprecision)	Only in research for anti-ageing claims [3], [5], [24]
Spermidine → memory/cognition	Pilot RCT positive (n=30); definitive 12-mo SmartAge RCT (n=100) null at 0.9 mg/day	Moderate (for null primary outcome)	Recommend against for cognition at low dose; higher-dose research needed [7], [25]
SGLT2 inhibitors → CV/mortality (as CR mimetic)	Strong RCT outcome data in cardiorenal disease; ageing-specific data absent	High (cardiorenal); Very low (healthy ageing — indirectness)	Use only for licensed cardiorenal/metabolic indications [8]

Cross-cutting limitations: small samples and wide CIs (imprecision); heterogeneous dosing and populations (inconsistency); reliance on biomarkers rather than function/mortality (indirectness); and probable publication bias in the supplement literature, with a documented tendency to overstate NR effects.[24][3]

4. Patient selection and indications

Because benefit on hard endpoints is unproven, patient selection is about identifying those most likely to gain and least likely to be harmed, under explicit informed consent.

– Potentially appropriate (consider, with consent):

– Middle-aged adults with cardiometabolic risk (central adiposity, insulin resistance, prediabetes) — favour lifestyle nutrient-sensing modulation (dietary restriction, TRE, exercise) as first line.[4][26][18]

– Adults specifically seeking mTOR modulation who understand it is experimental — candidate for research-framework low-dose rapamycin.[6][2]

– Exclusion / high-risk groups:

– Frank frailty, sarcopenia, low BMI, unintentional weight loss, or eating disorder → aggressive dietary restriction and mTOR inhibition risk accelerating muscle/bone loss.[12][27]

– Active or recent malignancy, active infection, poor wound healing, planned surgery → avoid rapamycin (immunosuppression).[1][2]

– Athletes or anyone whose primary goal is exercise-induced fitness/muscle gain → avoid metformin and peri-exercise rapamycin (both blunt training adaptation).[19][20][22]

– eGFR <30 mL/min/1.73m², significant hepatic impairment → avoid metformin (lactic acidosis risk); use specialist input.

– Regulatory/ethical status: All pharmacological interventions here are off-label for longevity. Best practice is to restrict rapamycin and NAD⁺ precursors to research or registry frameworks, or to offer as adjunctive care with documented informed consent only where the patient understands the absence of proven hard-outcome benefit.[3][1]

5. Assessment and baseline work-up

– History/examination: cardiometabolic and family longevity history; medication review (especially immunosuppressants, insulin/sulfonylureas); frailty screen; nutritional status and weight trajectory; exercise goals; infection/wound-healing risk; pregnancy status.

– Functional/scoring tools: grip strength, gait speed / chair-stand, and a frailty index in older adults; baseline cognition if spermidine/NAD⁺ contemplated.[12]

– Baseline investigations: FBC, U&E/eGFR, LFTs, HbA1c, fasting glucose/insulin (HOMA-IR), fasting lipids, hs-CRP; serum IGF-1 as a pathway biomarker; body composition by DXA (lean mass, visceral fat, bone density) where mTOR inhibition or restriction is planned.[6][23]

– Risk stratification: low risk = metabolically healthy, robust, normal renal/hepatic function; high risk = frailty/sarcopenia, immunocompromise, CKD/hepatic impairment, perioperative.

– Documentation for follow-up: baseline body composition, functional metrics, metabolic panel and IGF-1; record that ageing “biomarkers” (e.g. epigenetic clocks) are research tools without validated linkage to clinical outcomes and should not drive treatment decisions.[1]

6. Dosing regimens and practical implementation

Regimens supported by robust human data for the pathway (though not for longevity outcomes):

– Dietary restriction / time-restricted eating: the best-supported, lowest-risk approach; individualise to avoid undernutrition; ensure adequate protein in older adults to protect muscle. Expert-consensus, not guideline-mandated for longevity.[4][18][26]

Regimens extrapolated from early-phase data — use caution / research setting:

– Low-dose intermittent rapamycin (off-label): the PEARL RCT used 5–10 mg compounded rapamycin once weekly for 48 weeks with a placebo-comparable safety profile; RAPA-EX studies use ~6 mg weekly. Daily 1 mg in older adults produced more side effects and trends toward raised HbA1c/triglycerides. There is no validated titration or long-term protocol; therapeutic drug monitoring, optimal dose and duration are undefined.[6][23][28][2]

– NAD⁺ precursors (off-label supplement): trials of NR commonly ~250–1,000 mg/day and NMN ~250–900 mg/day reliably raise NAD⁺ and are well tolerated over weeks–months, but without consistent functional benefit; parenteral NAD⁺ has no outcome evidence.[24][3]

– Spermidine (food supplement): SmartAge used 0.9 mg/day wheat-germ extract for 12 months — well tolerated but no cognitive benefit; higher doses remain unstudied for efficacy.[7][25]

– Metformin (off-label for ageing): not recommended for healthy-ageing indications outside trials; the geroscience test dose is that of TAME. If used, be aware of exercise-adaptation blunting.[5][19][20]

Distinguish clearly: only lifestyle dietary restriction has a favourable risk–benefit balance for general use; all pharmacological regimens above rest on surrogate endpoints and short follow-up.[3][1]

7. Monitoring, safety and follow-up

– Rapamycin: monitor FBC (cytopenias — anaemia and altered red-cell indices reported), fasting glucose/HbA1c and lipids (potential hyperglycaemia/hyperlipidaemia), LFTs; clinical review for stomatitis/mouth ulcers, rash, GI upset (commonest AEs), and for infection or delayed wound healing. Suggested intervals: bloods at baseline, ~6 and 12 weeks after initiation/dose change, then 6-monthly. Hold peri-operatively and during significant infection.[28][2]

– NAD⁺ precursors: minimal specific monitoring beyond tolerability; reassure that these are generally well tolerated but efficacy unproven.[24][3]

– Metformin: eGFR and B12 periodically; counsel on GI effects and lactic-acidosis risk in renal/hepatic impairment.

– Ageing biomarkers: epigenetic clocks and similar may be tracked for research/engagement but must not be used to infer clinical benefit — the biomarker-to-outcome link is not validated.[1]

– Interactions: rapamycin is a CYP3A4/P-gp substrate — significant interactions with azoles, macrolides, diltiazem, grapefruit, statins; additive immunosuppression with other agents. Metformin + structured exercise blunts training gains; peri-exercise rapamycin similarly attenuates functional adaptation.[1][2][19][20][21][22]

– Special populations: contraindicated/avoid in pregnancy and breastfeeding (all agents); dose-avoid metformin in renal/hepatic impairment; in frailty and extremes of age, mTOR inhibition and caloric restriction risk muscle/bone loss and should generally be avoided or specialist-supervised.[12][27]

8. Contraindications and cautions

– Absolute: pregnancy/breastfeeding; active malignancy or serious active infection (rapamycin); severe renal (eGFR <30) or hepatic impairment (metformin); known hypersensitivity.

– Relative / specialist input: frailty, sarcopenia, low BMI or weight loss; planned surgery or poor wound healing (rapamycin); concurrent immunosuppression; interacting CYP3A4/P-gp drugs; uncontrolled dyslipidaemia or dysglycaemia (rapamycin); athletes/patients prioritising exercise adaptation (metformin, peri-exercise rapamycin).

– Harm likely to outweigh benefit: any pharmacological nutrient-sensing intervention pursued on the basis of biomarker “age reduction” alone, in an otherwise healthy person, given absent hard-outcome evidence.[3][1]

9. Practical management scenarios

Scenario A — Middle-aged adult with multiple cardiometabolic risk factors.

– Recommendation: Offer lifestyle nutrient-sensing modulation (dietary restriction/TRE, resistance + aerobic exercise, weight optimisation) — conditional recommendation. Consider a licensed agent (e.g. SGLT2 inhibitor or metformin) only where a conventional cardiometabolic/diabetes indication exists, per standard guidelines, not as a longevity drug.[4][18][26][8][5]

– Steps: baseline metabolic panel, HOMA-IR, DXA → shared decision-making emphasising lifestyle as best-evidenced → structured diet + supervised exercise → reassess HbA1c, lipids, weight and function at 3–6 months → escalate to conventional pharmacotherapy via primary care if thresholds crossed. Avoid metformin if the plan hinges on exercise-driven fitness gains.[19][20]

Scenario B — Older, frail patient with multimorbidity.

– Recommendation: Avoid rapamycin, aggressive caloric restriction and metformin-for-ageing — strong recommendation against, given muscle/bone, infection and adaptation risks.[12][27][19]

– Steps: assess frailty, nutrition and polypharmacy → prioritise protein-adequate nutrition, resistance exercise and deprescribing → treat reversible contributors → refer to geriatric/secondary care as needed. Any experimental agent only within a supervised trial.

Scenario C — Adjunct in a patient already under specialist care.

– Recommendation: Restrict to research/registry or defer — conditional against initiating off-label nutrient-sensing drugs without the specialist’s involvement, because of interaction and immunosuppression risks.[1][2]

– Steps: confirm indication and interacting medications → liaise with the treating specialist and document → if proceeding (e.g. within a rapamycin research protocol), baseline bloods/DXA, informed consent, monitoring at 6/12 weeks then 6-monthly → predefined stop criteria: cytopenia, rising HbA1c/triglycerides, recurrent stomatitis, infection, planned surgery, or unintended weight/muscle loss.[6][28]

10. Research gaps and future directions

– No completed RCT tests slowing of human ageing as a hard outcome. TAME (metformin, age-related multimorbidity) and VA-IMPACT are the key trials to watch.[5]

– Rapamycin: optimal dose, dosing interval, duration, monitoring, and long-term safety/efficacy in healthy adults are undefined; PEARL establishes short-term tolerability only. The apparent conflict with exercise adaptation needs resolution.[6][2][22]

– NAD⁺ precursors: despite reliable target engagement, clinically meaningful endpoints, correct precursor, dose, target population and parenteral routes remain unresolved; larger long-follow-up RCTs needed.[24][3]

– Spermidine: whether higher doses than 0.9 mg/day yield cognitive benefit requires a dedicated dose-ranging RCT.[7]

– Metformin–exercise interaction: identifying responders vs non-responders and mechanisms (e.g. mitochondrial/BCL6B-associated pathways) is a priority before pairing with exercise-based longevity programmes.[20][29]

– Biomarkers: validation linking epigenetic and other ageing clocks to clinical outcomes is essential before they guide therapy.[1]

Until such data mature, pharmacological nutrient-sensing modulation for longevity should ideally be confined to well-designed trials or registries, with lifestyle measures remaining the best-supported, lowest-risk intervention in routine practice.

References

1. Biomarkers of aging: from molecules and surrogates to physiology and function. Furrer R, Handschin C. Physiological Reviews. 2025;105(3):1609-1694. doi:10.1152/physrev.00045.2024.
2. Targeting the biology of aging with mTOR inhibitors. Mannick JB, Lamming DW. Nature Aging. 2023;3(6):642-660. doi:10.1038/s43587-023-00416-y.
3. NAD⁺ Supplementation for Anti-Aging and Wellness: A PRISMA-guided Systematic Review of Preclinical and Clinical Evidence. Gallagher C, Emmanuel OO. Ageing Research Reviews. 2026;116:103057. doi:10.1016/j.arr.2026.103057.
4. Evaluating the beneficial effects of dietary restrictions: A framework for precision nutrigeroscience. Wilson KA, Chamoli M, Hilsabeck TA, et al. Cell Metabolism. 2021;33(11):2142-2173. doi:10.1016/j.cmet.2021.08.018.
5. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
6. Influence of Rapamycin on Safety and Healthspan Metrics After One Year: PEARL Trial Results. Moel M, Harinath G, Lee V, et al. Aging. 2025;17(4):908-936. doi:10.18632/aging.206235.
7. Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline: A Randomized Clinical Trial. Schwarz C, Benson GS, Horn N, et al. JAMA Network Open. 2022;5(5):e2213875. doi:10.1001/jamanetworkopen.2022.13875.
8. SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases. Hoong CWS, Chua MWJ. Endocrinology. 2021;162(8):bqab079. doi:10.1210/endocr/bqab079.
9. Mitochondrial dysfunction in cell senescence and aging. Miwa S, Kashyap S, Chini E, von Zglinicki T. The Journal of Clinical Investigation. 2022;132(13):e158447. doi:10.1172/JCI158447.
10. Premature aging and metabolic diseases: the impact of telomere attrition. Jinesh S, Özüpek B, Aditi P. Frontiers in Aging. 2025;6:1541127. doi:10.3389/fragi.2025.1541127.
11. The Multifaceted Role of Nutrient Sensing and mTORC1 Signaling in Physiology and Aging. Fernandes SA, Demetriades C. Frontiers in Aging. 2021;2:707372. doi:10.3389/fragi.2021.707372.
12. Frailty in Older Adults. Kim DH, Rockwood K. The New England Journal of Medicine. 2024;391(6):538-548. doi:10.1056/NEJMra2301292.
13. Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Amorim JA, Coppotelli G, Rolo AP, et al. Nature Reviews. Endocrinology. 2022;18(4):243-258. doi:10.1038/s41574-021-00626-7.
14. Genetics of extreme human longevity to guide drug discovery for healthy ageing. Zhang ZD, Milman S, Lin JR, et al. Nature Metabolism. 2020;2(8):663-672. doi:10.1038/s42255-020-0247-0.
15. The metabolic regulation of aging. Finkel T. Nature Medicine. 2015;21(12):1416-23. doi:10.1038/nm.3998.
16. Combinatorial interventions in aging. Parkhitko AA, Filine E, Tatar M. Nature Aging. 2023;3(10):1187-1200. doi:10.1038/s43587-023-00489-9.
17. Dietary pyrroloquinoline quinone and spermidine in healthy longevity: targeting the hallmarks of aging. Numaguchi T, Nakamura M, Koshizawa T, Mohamad Ishak NS, Hashimoto K. Frontiers in Aging. 2026;7:1791853. doi:10.3389/fragi.2026.1791853.
18. Effects of Intermittent Fasting on Health, Aging, and Disease. de Cabo R, Mattson MP. The New England Journal of Medicine. 2019;381(26):2541-2551. doi:10.1056/NEJMra1905136.
19. Metformin Blunts Muscle Hypertrophy in Response to Progressive Resistance Exercise Training in Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial: The MASTERS Trial. Walton RG, Dungan CM, Long DE, et al. Aging Cell. 2019;18(6):e13039. doi:10.1111/acel.13039.
20. Metformin Inhibits Mitochondrial Adaptations to Aerobic Exercise Training in Older Adults. Konopka AR, Laurin JL, Schoenberg HM, et al. Aging Cell. 2019;18(1):e12880. doi:10.1111/acel.12880.
21. Exercise/Physical Activity in Individuals With Type 2 Diabetes: A Consensus Statement From the American College of Sports Medicine. Kanaley JA, Colberg SR, Corcoran MH, et al. Medicine and Science in Sports and Exercise. 2022;54(2):353-368. doi:10.1249/MSS.0000000000002800.
22. Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial. Stanfield B, Leroux B, Kaeberlein M, Jones J, Lucas R. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(2):e70274. doi:10.1002/jcsm.70274.
23. A Single-Center, Double-Blind, Randomized, Placebo-Controlled, Two-Arm Study to Evaluate the Safety and Efficacy of Once-Weekly Sirolimus (Rapamycin) on Muscle Strength and Endurance in Older Adults Following a 13-Week Exercise Program. Stanfield B, Kaeberlein M, Leroux B, et al. Trials. 2024;25(1):642. doi:10.1186/s13063-024-08490-2.
24. What Is Really Known About the Effects of Nicotinamide Riboside Supplementation in Humans. Damgaard MV, Treebak JT. Science Advances. 2023;9(29):eadi4862. doi:10.1126/sciadv.adi4862.
25. The Effect of Spermidine on Memory Performance in Older Adults at Risk for Dementia: A Randomized Controlled Trial. Wirth M, Benson G, Schwarz C, et al. Cortex; A Journal Devoted to the Study of the Nervous System and Behavior. 2018;109:181-188. doi:10.1016/j.cortex.2018.09.014.
26. Dietary Strategies With Anti-Aging Potential: Dietary Patterns and Supplements. Duan H, Pan J, Guo M, et al. Food Research International (Ottawa, Ont.). 2022;158:111501. doi:10.1016/j.foodres.2022.111501.
27. The Intersection of Frailty and Metabolism. Mishra M, Wu J, Kane AE, Howlett SE. Cell Metabolism. 2024;36(5):893-911. doi:10.1016/j.cmet.2024.03.012.
28. A Randomized Control Trial to Establish the Feasibility and Safety of Rapamycin Treatment in an Older Human Cohort: Immunological, Physical Performance, and Cognitive Effects. Kraig E, Linehan LA, Liang H, et al. Experimental Gerontology. 2018;105:53-69. doi:10.1016/j.exger.2017.12.026.
29. Metformin Suppresses the Mitochondrial and Transcriptional Response to Exercise, Revealing a Conserved BCL6B-associated Angiogenic Program. Bruss MD, Elliehausen CJ, Clark JP, Minton DM, Konopka AR. Journal of Applied Physiology (Bethesda, Md. : 1985). 2025;139(2):541-556. doi:10.1152/japplphysiol.00432.2025.